Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.
暂无分享,去创建一个
A. Kapoor | M. Jewett | G. Bjarnason | C. Kollmannsberger | D. Heng | L. Wood | D. Soulières | N. Basappa | E. Lévesque | A. Dragomir | S. Tanguay | M. Jewett | S. Nazha | N. Reaume | D.Y.C. Heng | L. Wood
[1] S. Hancock,et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] C. Porta,et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups , 2017, Annals of Oncology.
[3] N. Agarwal,et al. Real‐World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis , 2017, Clinical genitourinary cancer.
[4] A. Kapoor,et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. , 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[5] T. Choueiri,et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2016, European journal of cancer.
[6] T. Delea,et al. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. , 2016, Current oncology.
[7] L. Bergmann,et al. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies. , 2015, European journal of cancer.
[8] E. Jonasch,et al. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. , 2015, Clinical genitourinary cancer.
[9] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Jonasch,et al. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices , 2014, Current medical research and opinion.
[11] A. Kiss,et al. Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.
[12] R. Motzer,et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. , 2014, The New England journal of medicine.
[13] T. Bathala,et al. Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderClinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules , 2014 .
[14] R. Millikan,et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. , 2013, European journal of cancer.
[15] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[16] R. Breau,et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[17] T. Choueiri,et al. Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.
[18] K. Miller,et al. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors , 2013, World Journal of Urology.
[19] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[20] T. Choueiri,et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] M. Neary,et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics , 2012, Medical Oncology.
[22] K. Miller,et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. , 2011, European urology.
[23] T. Ecke,et al. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review. , 2010, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[24] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[25] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] C. Porta,et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.
[27] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Charbonneau,et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.
[29] Xu Zhang,et al. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..
[30] J. Lam,et al. Novel approaches in the therapy of metastatic renal cell carcinoma , 2005, World Journal of Urology.
[31] J. Patard,et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Wyman Sm,et al. Metastatic renal-cell carcinoma. , 1948, The New England journal of medicine.
[33] S. Hancock,et al. Kidney cancer, version 3.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[34] A. Kiss,et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.